[Clinical study of pravastatin with different dosage in early admission period in patients with unstable angina]

Zhonghua Xin Xue Guan Bing Za Zhi. 2005 Jan;33(1):54-7.
[Article in Chinese]

Abstract

Objective: To investigate the effect of early intervention by pravastatin with two different dosage on inflammatory factors and endothelial vasodilator function in patients with unstable angina (UA).

Methods: 108 patients with UA were investigated consecutively and divided randomly into three groups (group 20 mg, n = 37; group 10 mg, n = 37; group control, n = 34). Blood samples were examined at admission and 4, 8 weeks after the therapy of pravastatin. Fourty patients of UA were chosen from those three groups (15, 15 and 10 cases respectively). The endothelium-dependent vasodilation and the function of vascular endothelium of them were measured. In the dosage of 20 mg pravastatin group non-endothelium-dependent vasodilation in brachial artery was also tested by ultrasound before and 8 weeks after the therapy. Cardiac events were followed up for 2 months.

Results: (1) The use of pravastatin in early admission period of UA could significantly reduce inflammatory factors and improve vascular endothelium function, which was more obviously in the group of 20 mg/d than in group of 10 mg/d. These benefits occurred in 4th week and more obviously in 8th week after the therapy. (2) The lipid lowering therapy in the early stage of admission (24 - 48 h) resulted in the reduction of cardiac events in the hospital.

Conclusion: The use of pravastatin 20 mg/d seems better than that of 10 mg/d in all the fields as above in early admission period of UA patients.

Publication types

  • English Abstract
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Angina, Unstable / drug therapy*
  • Anticholesteremic Agents / administration & dosage*
  • Anticholesteremic Agents / therapeutic use
  • Female
  • Follow-Up Studies
  • Humans
  • Inpatients
  • Male
  • Middle Aged
  • Pravastatin / administration & dosage*
  • Pravastatin / therapeutic use
  • Prospective Studies

Substances

  • Anticholesteremic Agents
  • Pravastatin